The neuropeptide systems and their potential role in the treatment of mammalian retinal ischemia: A developing story

Current Neuropharmacology

Volumn 11, Issue 1, 2013, Pages 95-101

  Cervia, D ^a   Casini, G ^a  

^a UNIVERSITY OF TUSCIA   (Italy)

Author keywords

Angiotensin; Glutamate release; Neuronal death; Opioid peptides; PACAP; Peptide receptors; Somatostatin

Indexed keywords

ANGIOTENSIN II; CORTICOTROPIN RELEASING FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; OPIATE PEPTIDE; REACTIVE OXYGEN METABOLITE; SODIUM AZIDE; SOMATOSTATIN; UROCORTIN II;

BLINDNESS; CELL DEATH; CELL MEMBRANE DEPOLARIZATION; CYTOKINE PRODUCTION; DNA DAMAGE; HUMAN; INFLAMMATION; NEUROTRANSMISSION; NONHUMAN; OXYGEN CONSUMPTION; PEPTIDERGIC NERVOUS SYSTEM; PROTEIN EXPRESSION; RETINA CELL; RETINA ISCHEMIA; REVIEW; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

EID: 84874855806     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159x11311010011     Document Type: Review

References (83)

1. Strand, F.L. Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders. Prog. Drug. Res., 2003, 61, 1-37.
2. Merighi, A. Costorage and coexistence of neuropeptides in the mammalian CNS. Prog. Neurobiol., 2002, 66(3), 161-190.
3. Bunnett, N.W.; Cottrell, G.S. Trafficking and signaling of G protein-coupled receptors in the nervous system: implications for disease and therapy. CNS Neurol. Disord. Drug Targets, 2010, 9(5), 539-556.
4. Bomberger, J.M.; Parameswaran, N.; Spielman, W.S. Regulation of GPCR trafficking by RAMPs. Adv. Exp. Med. Biol., 2012, 744, 25-37.
5. Barwell, J.; Wootten, D.; Simms, J.; Hay, D.L.; Poyner, D.R. RAMPs and CGRP receptors. Adv. Exp. Med. Biol., 2012, 744, 13-24.
6. Bockaert, J.; Perroy, J.; Becamel, C.; Marin, P.; Fagni, L. GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. Annu. Rev. Pharmacol. Toxicol., 2010, 50, 89-109.
7. Pineyro, G. Membrane signalling complexes: implications for development of functionally selective ligands modulating heptahelical receptor signalling. Cell Signal., 2009, 21(2), 179-185.
8. McGonigle, P. Peptide therapeutics for CNS indications. Biochem. Pharmacol., 2012, 83(5), 559-566.
9. Osborne, N.N.; Casson, R.J.; Wood, J.P.; Chidlow, G.; Graham, M.; Melena, J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog. Retin. Eye Res., 2004, 23(1), 91-147.
10. Stitt, A.W.; O'Neill, C.L.; O'Doherty, M.T.; Archer, D.B.; Gardiner, T.A.; Medina, R.J. Vascular stem cells and ischaemic retinopathies. Prog. Retin. Eye Res., 2011, 30(3), 149-166.
11. Minhas, G.; Morishita, R.; Anand, A. Preclinical models to investigate retinal ischemia: advances and drawbacks. Front. Neurol., 2012, 3, 75.
12. Bek, T. Inner retinal ischaemia: current understanding and needs for further investigations. Acta Ophthalmol., 2009, 87(4), 362-367.
13. Fulton, A.B.; Akula, J.D.; Mocko, J.A.; Hansen, R.M.; Benador, I.Y.; Beck, S.C.; Fahl, E.; Seeliger, M.W.; Moskowitz, A.; Harris, M.E. Retinal degenerative and hypoxic ischemic disease. Doc. Ophthalmol., 2009, 118(1), 55-61.
14. Rajappa, M.; Saxena, P.; Kaur, J. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv. Clin. Chem., 2010, 50, 103-121.
15. Sapieha, P.; Hamel, D.; Shao, Z.; Rivera, J.C.; Zaniolo, K.; Joyal, J.S.; Chemtob, S. Proliferative retinopathies: angiogenesis that blinds. Int. J. Biochem. Cell Biol., 2010, 42(1), 5-12.
16. Bagnoli, P.; Dal Monte, M.; Casini, G. Expression of neuropeptides and their receptors in the developing retina of mammals. Histol. Histopathol., 2003, 18(4), 1219-1242.
17. Brazeau, P.; Vale, W.; Burgus, R.; Ling, N.; Butcher, M.; Rivier, J.; Guillemin, R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science, 1973, 179(4068), 77-79.
18. Cervia, D.; Bagnoli, P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol. Ther., 2007, 116(2), 322-341.
19. Patel, Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol., 1999, 20(3), 157-198.
20. Cervia, D.; Casini, G.; Bagnoli, P. Physiology and pathology of somatostatin in the mammalian retina: a current view. Mol. Cell. Endocrinol., 2008, 286(1-2), 112-122.
21. Weckbecker, G.; Lewis, I.; Albert, R.; Schmid, H.A.; Hoyer, D.; Bruns, C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug. Discov., 2003, 2(12), 999-1017.
22. Cervia, D.; Fehlmann, D.; Hoyer, D. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 367(6), 578-587.
23. Cervia, D.; Nunn, C.; Fehlmann, D.; Langenegger, D.; Schuepbach, E.; Hoyer, D. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br. J. Pharmacol., 2003, 139(1), 109-121.
24. Cervia, D.; Langenegger, D.; Schuepbach, E.; Cammalleri, M.; Schoeffter, P.; Schmid, H.A.; Bagnoli, P.; Hoyer, D. Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors. Neuropharmacology, 2005, 48(6), 881-893.
25. Schmid, H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol. Cell. Endocrinol., 2008, 286(1-2), 69-74.
26. Helboe, L.; Moller, M. Immunohistochemical localization of somatostatin receptor subtypes sst1 and sst2 in the rat retina. Invest. Ophthalmol. Vis. Sci., 1999, 40(10), 2376-2382.
27. Cristiani, R.; Fontanesi, G.; Casini, G.; Petrucci, C.; Viollet, C.; Bagnoli, P. Expression of somatostatin subtype 1 receptor in the rabbit retina. Invest. Ophthalmol. Vis. Sci., 2000, 41(10), 3191-3199.
28. Dal Monte, M.; Petrucci, C.; Vasilaki, A.; Cervia, D.; Grouselle, D.; Epelbaum, J.; Kreienkamp, H.J.; Richter, D.; Hoyer, D.; Bagnoli, P. Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. Neuropharmacology, 2003, 45(8), 1080-1092.
29. Mastrodimou, N.; Thermos, K. The somatostatin receptor (sst1) modulates the release of somatostatin in rat retina. Neurosci. Lett., 2004, 356(1), 13-16.
30. Johnson, J.; Wong, H.; Walsh, J.H.; Brecha, N.C. Expression of the somatostatin subtype 2A receptor in the rabbit retina. J. Comp. Neurol., 1998, 393(1), 93-101.
31. Johnson, J.; Wu, V.; Wong, H.; Walsh, J.H.; Brecha, N.C. Somatostatin receptor subtype 2A expression in the rat retina. Neuroscience, 1999, 94(3), 675-683.
32. Fontanesi, G.; Gargini, C.; Bagnoli, P. Postnatal development of somatostatin 2A (sst2A) receptors expression in the rabbit retina. Brain Res. Dev. Brain Res., 2000, 123(1), 67-80.
33. Petrucci, C.; Resta, V.; Fieni, F.; Bigiani, A.; Bagnoli, P. Modulation of potassium current and calcium influx by somatostatin in rod bipolar cells isolated from the rabbit retina via sst2 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2001, 363(6), 680-694.
34. Vasilaki, A.; Gardette, R.; Epelbaum, J.; Thermos, K. NADPHdiaphorase colocalization with somatostatin receptor subtypes sst2A and sst2B in the retina. Invest. Ophthalmol. Vis. Sci., 2001, 42(7), 1600-1609.
35. Cristiani, R.; Petrucci, C.; Dal Monte, M.; Bagnoli, P. Somatostatin (SRIF) and SRIF receptors in the mouse retina. Brain Res., 2002, 936(1-2), 1-14.
36. Dal Monte, M.; Petrucci, C.; Cozzi, A.; Allen, J.P.; Bagnoli, P. Somatostatin inhibits potassium-evoked glutamate release by activation of the sst(2) somatostatin receptor in the mouse retina. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 367(2), 188-192.
37. Ke, J.B.; Zhong, Y.M. Expression of somatostatin receptor subtype 5 in rat retinal amacrine cells. Neuroscience, 2007, 144(3), 1025-1032.
38. Wu, X.H.; Deng, Q.Q.; Jiang, S.X.; Yang, X.L.; Zhong, Y.M. Distribution of somatostatin receptor 5 in mouse and bullfrog retinas. Peptides, 2012, 33(2), 291-297.
39. Mastrodimou, N.; Lambrou, G.N.; Thermos, K. Effect of somatostatin analogues on chemically induced ischaemia in the rat retina. Naunyn Schmiedebergs Arch. Pharmacol., 2005, 371(1), 44-53.
40. Catalani, E.; Cervia, D.; Martini, D.; Bagnoli, P.; Simonetti, E.; Timperio, A.M.; Casini, G. Changes in neuronal response to ischemia in retinas with genetic alterations of somatostatin receptor expression. Eur. J. Neurosci., 2007, 25(5), 1447-1459.
41. Cervia, D.; Martini, D.; Ristori, C.; Catalani, E.; Timperio, A.M.; Bagnoli, P.; Casini, G. Modulation of the neuronal response to ischaemia by somatostatin analogues in wild-type and knock-out mouse retinas. J. Neurochem., 2008, 106(5), 2224-2235.
42. Kiagiadaki, F.; Thermos, K. Effect of intravitreal administration of somatostatin and sst2 analogs on AMPA-induced neurotoxicity in rat retina. Invest. Ophthalmol. Vis. Sci., 2008, 49(7), 3080-3089.
43. Casini, G.; Catalani, E.; Dal Monte, M.; Bagnoli, P. Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease. Histol. Histopathol., 2005, 20(2), 615-632.
44. Bigiani, A.; Petrucci, C.; Ghiaroni, V.; Dal Monte, M.; Cozzi, A.; Kreienkamp, H.J.; Richter, D.; Bagnoli, P. Functional correlates of somatostatin receptor 2 overexpression in the retina of mice with genetic deletion of somatostatin receptor 1. Brain Res., 2004, 1025(1-2), 177-185.
45. Pavan, B.; Fiorini, S.; Dal Monte, M.; Lunghi, L.; Biondi, C.; Bagnoli, P.; Cervia, D. Somatostatin coupling to adenylyl cyclase activity in the mouse retina. Naunyn Schmiedebergs Arch. Pharmacol., 2004, 370(2), 91-98.
46. Cervia, D.; Catalani, E.; Dal Monte, M.; Casini, G. Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin. J. Neurochem., 2012, 120(5), 818-829.
47. Mastrodimou, N.; Kiagiadaki, F.; Thermos, K. The role of nitric oxide and cGMP in somatostatin's protection against retinal ischemia. Invest. Ophthalmol. Vis. Sci., 2008, 49(1), 342-349.
48. Zhou, C.J.; Shioda, S.; Yada, T.; Inagaki, N.; Pleasure, S.J.; Kikuyama, S. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr. Protein Pept. Sci., 2002, 3(4), 423-439.
49. Said, S.I.; Mutt, V. Polypeptide with broad biological activity: isolation from small intestine. Science, 1970, 169(3951), 1217-1218.
50. Seki, T.; Shioda, S.; Ogino, D.; Nakai, Y.; Arimura, A.; Koide, R. Distribution and ultrastructural localization of a receptor for pituitary adenylate cyclase activating polypeptide and its mRNA in the rat retina. Neurosci. Lett., 1997, 238(3), 127-130.
51. Seki, T.; Shioda, S.; Nakai, Y.; Arimura, A.; Koide, R. Distribution and ultrastructural localization of pituitary adenylate cyclaseactivating polypeptide (PACAP) and its receptor in the rat retina. Ann. N Y Acad. Sci., 1998, 865, 408-411.
52. Seki, T.; Izumi, S.; Shioda, S.; Zhou, C.J.; Arimura, A.; Koide, R. Gene expression for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ RT-PCR. Ann. N Y Acad. Sci., 2000, 921, 366-369.
53. Casini, G.; Brecha, N.C. Vasoactive intestinal polypeptidecontaining cells in the rabbit retina: immunohistochemical localization and quantitative analysis. J. Comp. Neurol., 1991, 305(2), 313-327.
54. Okamoto, S.; Okamura, H.; Terubayashi, H.; Akagi, Y.; Okamoto, H.; Ibata, Y. Localization of vasoactive intestinal peptide (VIP) messenger RNA (mRNA) in amacrine cells of rat retina. Curr. Eye Res., 1992, 11(7), 711-715.
55. Casini, G.; Molnar, M.; Brecha, N.C. Vasoactive intestinal polypeptide/peptide histidine isoleucine messenger RNA in the rat retina: adult distribution and developmental expression. Neuroscience, 1994, 58(3), 657-667.
56. Atlasz, T.; Szabadfi, K.; Kiss, P.; Racz, B.; Gallyas, F.; Tamas, A.; Gaal, V.; Marton, Z.; Gabriel, R.; Reglodi, D. Pituitary adenylate cyclase activating polypeptide in the retina: focus on the retinoprotective effects. Ann. N.Y. Acad. Sci., 2010, 1200, 128-139.
57. Seki, T.; Itoh, H.; Nakamachi, T.; Endo, K.; Wada, Y.; Nakamura, K.; Shioda, S. Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure. J. Mol. Neurosci., 2011, 43(1), 30-34.
58. Szabadfi, K.; Atlasz, T.; Kiss, P.; Danyadi, B.; Tamas, A.; Helyes, Z.; Hashimoto, H.; Shintani, N.; Baba, A.; Toth, G.; Gabriel, R.; Reglodi, D. Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox. Res., 2012, 21(1), 41-48.
59. Endo, K.; Nakamachi, T.; Seki, T.; Kagami, N.; Wada, Y.; Nakamura, K.; Kishimoto, K.; Hori, M.; Tsuchikawa, D.; Shinntani, N.; Hashimoto, H.; Baba, A.; Koide, R.; Shioda, S. Neuroprotective effect of PACAP against NMDA-induced retinal damage in the mouse. J. Mol. Neurosci., 2011, 43(1), 22-29.
60. Atlasz, T.; Szabadfi, K.; Kiss, P.; Tamas, A.; Toth, G.; Reglodi, D.; Gabriel, R. Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res. Bull., 2010, 81(4-5), 497-504.
61. Szabadfi, K.; Danyadi, B.; Kiss, P.; Tamas, A.; Fabian, E.; Gabriel, R.; Reglodi, D. Protective Effects of Vasoactive Intestinal Peptide (VIP) in Ischemic Retinal Degeneration. J. Mol. Neurosci., 2012
62. Nock, B.; Giordano, A.L.; Moore, B.W.; Cicero, T.J. Properties of the putative epsilon opioid receptor: identification in rat, guinea pig, cow, pig and chicken brain. J. Pharmacol. Exp. Ther., 1993, 264(1), 349-359.
63. Tseng, L.F.; Henneberry, B.; Collins, K.A. The antinociception induced by beta-endorphin administered intrathecally is mediated by the activation of mu-and kappa-opioid receptors in the rat. Naunyn Schmiedebergs Arch. Pharmacol., 1995, 351(5), 464-468.
64. Tseng, L.F.; Tsai, J.H.; Collins, K.A.; Portoghese, P.S. Spinal delta 2-, but not delta 1-, mu-, or kappa-opioid receptors are involved in the tail-flick inhibition induced by beta-endorphin from nucleus raphe obscurus in the pentobarbital-anesthetized rat. Eur. J. Pharmacol., 1995, 277(2-3), 251-256.
65. Altschuler, R.A.; Mosinger, J.L.; Hoffman, D.W.; Parakkal, M.H. Immunocytochemical localization of enkephalin-like immunoreactivity in the retina of the guinea pig. Proc. Natl. Acad. Sci. U. S. A., 1982, 79(7), 2398-2400.
66. Peng, P.H.; Huang, H.S.; Lee, Y.J.; Chen, Y.S.; Ma, M.C. Novel role for the delta-opioid receptor in hypoxic preconditioning in rat retinas. J. Neurochem., 2009, 108(3), 741-754.
67. Gallagher, S.K.; Witkovsky, P.; Roux, M.J.; Low, M.J.; Otero-Corchon, V.; Hentges, S.T.; Vigh, J. beta-Endorphin expression in the mouse retina. J. Comp. Neurol., 2010, 518(15), 3130-3148.
68. Brecha, N.; Kui, B.; Anton, B.; Keith, D.; Evans, C.; Sternini, C. Mu opioid receptor immunoreactivity is expressed in the retina and retina recipient nuclei. Analgesia, 1995, 1, 331-334.
69. Gallagher, S.K.; Anglen, J.N.; Mower, J.M.; Vigh, J. Dopaminergic amacrine cells express opioid receptors in the mouse retina. Vis. Neurosci., 2012, 29(3), 203-209.
70. Husain, S.; Potter, D.E.; Crosson, C.E. Opioid receptor-activation: retina protected from ischemic injury. Invest. Ophthalmol. Vis. Sci., 2009, 50(8), 3853-3859.
71. Husain, S.; Liou, G.I.; Crosson, C.E. Opioid receptor activation: suppression of ischemia/reperfusion-induced production of TNFalpha in the retina. Invest. Ophthalmol. Vis. Sci., 2011, 52(5), 2577-2583.
72. Riazi-Esfahani, M.; Kiumehr, S.; Asadi-Amoli, F.; Lashay, A.R.; Dehpour, A.R. Morphine pretreatment provides histologic protection against ischemia-reperfusion injury in rabbit retina. Retina, 2008, 28(3), 511-517.
73. Riazi-Esfahani, M.; Kiumehr, S.; Asadi-Amoli, F.; Dehpour, A.R. Effects of intravitreal morphine administered at different time points after reperfusion in a rabbit model of ischemic retinopathy. Retina, 2009, 29(2), 262-268.
74. McKinley, M.J.; Albiston, A.L.; Allen, A.M.; Mathai, M.L.; May, C.N.; McAllen, R.M.; Oldfield, B.J.; Mendelsohn, F.A.; Chai, S.Y. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell Biol., 2003, 35(6), 901-918.
75. Wilkinson-Berka, J.L.; Fletcher, E.L. Angiotensin and bradykinin: targets for the treatment of vascular and neuro-glial pathology in diabetic retinopathy. Curr. Pharm. Des., 2004, 10(27), 3313-3330.
76. Downie, L.E.; Vessey, K.; Miller, A.; Ward, M.M.; Pianta, M.J.; Vingrys, A.J.; Wilkinson-Berka, J.L.; Fletcher, E.L. Neuronal and glial cell expression of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in the rat retina. Neuroscience, 2009, 161(1), 195-213.
77. Fukuda, K.; Hirooka, K.; Mizote, M.; Nakamura, T.; Itano, T.; Shiraga, F. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor. Invest. Ophthalmol. Vis. Sci., 2010, 51(7), 3629-3638.
78. Yang, H.; Hirooka, K.; Fukuda, K.; Shiraga, F. Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma. Invest. Ophthalmol. Vis. Sci., 2009, 50(12), 5800-5804.
79. Szabadfi, K.; Atlasz, T.; Reglodi, D.; Kiss, P.; Danyadi, B.; Fekete, E.M.; Zorrilla, E.P.; Tamas, A.; Szabo, K.; Gabriel, R. Urocortin 2 protects against retinal degeneration following bilateral common carotid artery occlusion in the rat. Neurosci. Lett., 2009, 455(1), 42-45.
80. Nucci, C.; Gasperi, V.; Tartaglione, R.; Cerulli, A.; Terrinoni, A.; Bari, M.; De Simone, C.; Agro, A.F.; Morrone, L.A.; Corasaniti, M.T.; Bagetta, G.; Maccarrone, M. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest. Ophthalmol. Vis. Sci., 2007, 48(7), 2997-3004.
81. Jehle, T.; Dimitriu, C.; Auer, S.; Knoth, R.; Vidal-Sanz, M.; Gozes, I.; Lagreze, W.A. The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush. Graefes Arch. Clin. Exp. Ophthalmol., 2008, 246(9), 1255-1263.
82. Chan, A.S.; Saraswathy, S.; Rehak, M.; Ueki, M.; Rao, N.A. Neuroglobin protection in retinal ischemia. Invest. Ophthalmol. Vis. Sci., 2012, 53(2), 704-711.
83. Danesh-Meyer, H.V.; Kerr, N.M.; Zhang, J.; Eady, E.K.; O'Carroll, S.J.; Nicholson, L.F.; Johnson, C.S.; Green, C.R. Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following retinal ischaemia. Brain, 2012, 135(Pt 2), 506-520.